Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.57 |
| ▸ | PARP1 | P09874 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352632 | 0.81 | PARP1 (0.62) | PARP1 | |
| SCHEMBL28018259 | 0.74 | AR (0.63) | ARPARP1LMNAPRMT5 | |
| SCHEMBL3351861 | 0.74 | PARP1 (0.65) | ARPARP1LMNATSHRKDM4E | |
| SCHEMBL863462 | 0.74 | AR (1.00) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL5717747 | 0.72 | LMNA (1.00) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL30151141 | 0.72 | LMNA (1.00) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL77913 | 0.71 | PARP1 (0.73) | ARPARP1 | |
| SCHEMBL3352195 | 0.71 | TSHR (0.59) | ARPARP1LMNATSHRPRMT5 | |
| SCHEMBL30416453 | 0.71 | PARP1 (0.73) | ARPARP1 | |
| SCHEMBL31172890 | 0.71 | ENPP1 (0.59) | ARPARP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101048399-B | 4-hetero aryl methyl substituted phthalazinone derivatives | KUDOS PHARM LTD | 2010-09-01 | — | — | CN | disclosed |
| US-7666870-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2010-02-23 | — | — | US | disclosed |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7407957-B2 | e.g. 4-[5-(piperazine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent; septic shock; ischemic injury; reperfusion injury; hemorrhagic shock; and multiple sclerosis | MAYBRIDGE LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| CN-101048399-A | 4-hetero aryl methyl substituted phthalazinone derivatives | KUDOS PHARM LTD (GB) | 2007-10-03 | — | — | CN | disclosed |
| EP-1791827-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2007-06-06 | — | — | EP | disclosed |
| US-20060063767-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LTD (GB) | 2006-03-23 | — | — | US | disclosed |
| WO-2006021801-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | PARP1, PARP2, PARP11 | AR 190/4885PARP1 1/4885LMNA 516/4885 |
| US-20060063767-A1 | Phthalazinone derivatives | PARP1, PARP2, NR0B1 | AR 155/4885PARP1 1/4885LMNA 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.